Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancerRyan D Foster; Yair Lotan; David A Pistenmaa; Robert Timmerman; Xian-Jin Xie)
Journal of Clinical Oncology. 2011;29(15):2020-2026.Abstract
Purpose: To evaluate the tolerability of escalating doses of stereotactic body radiation therapy in the treatment of localized prostate cancer. Patients and Methods: Eligible patients included those with Gleason score 2 to 6 with prostate-specific antigen (PSA) ≤ 20, Gleason score 7 with PSA ≤ 15, ≤ T2b, prostate size ≤ 60 cm3, and American Urological Association (AUA) score ≤ 15. Pretreatment preparation required an enema and placement of a rectal balloon. Dose-limiting toxicity (DLT) was defined as grade 3 or worse GI/genitourinary (GU) toxicity by Common Terminology Criteria of Adverse Events (version 3). Patients completed quality-of-life questionnaires at defined intervals. Results: Groups of 15 patients received 45 Gy, 47.5 Gy, and 50 Gy in five fractions (45 total patients). The median follow-up is 30 months (range, 3 to 36 months), 18 months (range, 0 to 30 months), and 12 months (range, 3 to 18 months) for the 45 Gy, 47.5 Gy, and 50 Gy groups, respectively. For all patients, GI grade ≥ 2 and grade ≥ 3 toxicity occurred in 18% and 2%, respectively, and GU grade ≥ 2 and grade ≥ 3 toxicity occurred in 31% and 4%, respectively. Mean AUA scores increased significantly from baseline in the 47.5-Gy dose level (P = .002) as compared with the other dose levels, where mean values returned to baseline. Rectal quality-of-life scores (Expanded Prostate Cancer Index Composite) fell from baseline up to 12 months but trended back at 18 months. In all patients, PSA control is 100% by the nadir + 2 ng/mL failure definition. Conclusion: Dose escalation to 50 Gy has been completed without DLT. A multicenter phase II trial is underway treating patients to 50 Gy in five fractions to further evaluate this experimental therapy. © 2011 by American Society of Clinical Oncology.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
D.W. Nathan Kim; L. Chinsoo Cho; Christopher Straka; Alana Christie; Yair Lotan; David Pistenmaa; Brian D. Kavanagh; Akash Nanda; Patrick Kueplian; Jeffrey Brindle; et al.International Journal of Radiation Oncology Biology Physics. 2014;89(3):509-517.
Simon S. Lo; Achilles J. Fakiris; Eric L. Chang; Nina A. Mayr; Jian Z. Wang; Lech Papiez; Bin S. Teh; Ronald C. McGarry; Higinia R. Cardenes; Robert D. TimmermanNature Reviews Clinical Oncology. 2010;7(1):44-54.
Kevin G. Billingsley; Charles Maynard; David L. Schwartz; Jason A. DominitzCancer. 2001;92(5):1281-1287.
Appears in this Document